Exenatide
Adjunctive therapy to diet and exercise to improve glycemic control in patients with type 2-diabetes mellitus.
Adult : subcutaneous is thigh, abdomen or upper arm : initial dose = 5 mcg twice daily within 60 minutes period before morning and evening meal. If clinical response is not adequate within one month increase dosage to 10 mcg twice a day.
Standard consideration. Do not use in patients with type 1-diabetes and diabetic ketoacidosis. Hypersensitivity.
Do not administered after a meal. Pregnancy, Lactation and children. ESRD or sever renal function impairment, severe G I disease, pancreatitis. Anti-exenatide antibodies may develop.
Hypersensitivity reaction; injection site reaction; dizziness, headache, asthenia, decreased appetite, somnolence, hyperhydrosis, pruritus, rash, urticaria, nausea, vomiting, diarrhea, constipation, dyspepsia, gastroesophageal reflux, abdominal distention, abdominal pain, dysgensia, eructation, flatulence, acute pancreatitis, haemorrhagic and necrotizing pancreatitis sometimes resulting in death. Renal impairment, kidney transplant dysfunction, increase serum creatinine.
Acetaminophen, Digoxin, drugs that require rapid GI absorption (eg. Antibiotics, oral contraceptives hypoglycaemic agents, lovastatin, warfarin.
